Palliative Care in Chronic Liver Disease

Last updated 1 Jun 2026 · Palliative care

📋 Key Information Summary

📋

End-stage liver disease (ESLD) causes a high symptom burden including pain, fatigue, pruritus, nausea, and muscle cramps that require proactive palliative management.
Prognostic uncertainty is characteristic — clinicians should use validated tools (MELD, Child-Pugh) alongside clinical judgement to guide goals-of-care conversations.
Ascites management combines sodium restriction (<2 g/day), diuretics (spironolactone ± frusemide), and large-volume paracentesis with albumin replacement.
Refractory ascites with a MELD score ≥18 carries a 6-month mortality of approximately 50%; early palliative care referral should be considered.
Hepatic encephalopathy (HE) is managed with lactulose (target 2–3 soft stools/day) and rifaximin; recurrent HE despite treatment is an ominous prognostic sign.
Variceal bleeding requires emergency endoscopy, vasoactive drugs (terlipressin or octreotide), and antibiotics (ceftriaxone); recurrent bleeding carries high mortality.
Child-Pugh C cirrhosis with MELD ≥15 or recurrent decompensation episodes should trigger a palliative care needs assessment regardless of transplant candidacy.
Transplant assessment and palliative care are not mutually exclusive — concurrent planning improves symptom control and patient satisfaction.
End-of-life symptom management in ESLD requires caution with benzodiazepines and opioids due to impaired hepatic metabolism; dose reduction and careful titration are essential.
Aboriginal and Torres Strait Islander Australians experience liver disease at 3–5 times the rate of non-Indigenous Australians, with later presentation and greater barriers to specialist and palliative care.
Advance care planning should be initiated early and revisited at each decompensation episode; documentation must be accessible across care settings.
Hepatorenal syndrome (HRS) type 1 has a median survival of 2 weeks without treatment; goals-of-care discussions are critical at diagnosis.

Introduction & Australian Epidemiology

Chronic liver disease (CLD) is a leading cause of morbidity and mortality in Australia. The progressive nature of end-stage liver disease results in a complex symptom trajectory marked by episodes of acute-on-chronic liver failure, accumulating complications, and prognostic uncertainty. Unlike many malignancies where palliative care integration is well established, patients with ESLD often receive palliative care late or not at all, despite carrying a symptom burden comparable to advanced cancer.

In 2022, liver disease accounted for approximately 8,000 deaths in Australia, with chronic liver disease and cirrhosis ranked among the top 20 causes of death nationally. Hepatitis C-related cirrhosis has declined following direct-acting antiviral (DAA) availability, but alcohol-related liver disease (ALD) and non-alcoholic steatohepatitis (NASH) are rising. ALD is now the most common indication for liver transplantation in Australia.

⚠️

Palliative care gap: Fewer than 20% of patients dying from ESLD in Australia access specialist palliative care services, compared with over 50% of patients with metastatic cancer. Late referral limits the opportunity for advance care planning, effective symptom management, and support for families.

This guideline addresses the palliative management of the four principal complication domains in ESLD: ascites and oedema, hepatic encephalopathy, bleeding risk (portal hypertensive and coagulopathic), and the interface between transplant assessment and goals of care. It is intended for general practitioners, palliative care physicians, gastroenterologists, and hospital-based clinicians managing patients with decompensated cirrhosis in the Australian healthcare setting.

Aetiology	Proportion of Cirrhosis Cases (Australia)	Trend
Alcohol-related liver disease	~40%	Rising
Non-alcoholic steatohepatitis (NASH / MAFLD)	~25%	Rising rapidly
Hepatitis C (cured or active)	~20%	Declining post-DAA
Hepatitis B	~8%	Stable
Autoimmune / cholestatic / other	~7%	Stable

Ascites & Oedema

Ascites is the most common decompensating event in cirrhosis, developing in approximately 60% of patients within 10 years of diagnosis. Its presence signals a significant shift in prognosis — median survival drops from >10 years (compensated) to approximately 2 years without transplantation (decompensated with ascites).

Pathophysiology

Portal hypertension (hepatic venous pressure gradient >10 mmHg) drives sodium and water retention via activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system, and non-osmotic vasopressin release. Reduced effective arterial blood volume leads to renal sodium avidity. Hypoalbuminaemia (<30 g/L) further decreases oncotic pressure, promoting fluid transudation into the peritoneal cavity and interstitial tissues.

Assessment & Classification

Grade	Description	Management Approach
Grade 1 (Mild)	Detectable only by ultrasound	Sodium restriction alone
Grade 2 (Moderate)	Moderate symmetrical abdominal distension	Sodium restriction + diuretics
Grade 3 (Tense / Large)	Marked distension, tense, respiratory compromise	Large-volume paracentesis + diuretics
Refractory	Diuretic-resistant or diuretic-intractable	Serial paracentesis, TIPS consideration, palliative focus

Diagnostic Paracentesis

Diagnostic ascitic tap is mandatory at first presentation and whenever there is clinical suspicion of spontaneous bacterial peritonitis (SBP). Send fluid for cell count and differential, protein, albumin, culture (in blood culture bottles), and cytology if malignancy is suspected. Calculate the serum–ascites albumin gradient (SAAG): a SAAG ≥11 g/L confirms portal hypertension as the cause with >97% accuracy.

🚨

SBP diagnosis: An ascitic fluid polymorphonuclear (PMN) count ≥250 cells/mm³ is diagnostic of SBP, even if the culture is negative. Empirical IV ceftriaxone 2 g daily (or IV cefotaxime 2 g TDS) must be commenced immediately and continued for 5 days. IV albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 reduces renal impairment and mortality.

Pharmacological Management

💊

Spironolactone

Aldactone® · Spiractin® · Aldosterone antagonist

Adult dose 100 mg PO mane, titrate every 5–7 days to max 400 mg/day

Paediatric dose 1–3 mg/kg/day PO in 1–2 divided doses (max 100 mg/day)

Renal adjustment Avoid if eGFR <30 mL/min (risk of hyperkalaemia); monitor K⁺ closely

Key notes First-line for ascites. Gynaecomastia common. Monitor serum potassium and sodium.

PBS status ✔ PBS General Benefit

💊

Frusemide

Lasix® · Uremide® · Loop diuretic

Adult dose 40 mg PO mane, titrate to max 160 mg/day (maintain 100:40 spironolactone:frusemide ratio)

Paediatric dose 1–2 mg/kg/dose PO/IV (max 6 mg/kg/day)

Renal adjustment Dose reduction may be needed; higher doses required in renal impairment

Key notes Used in combination with spironolactone. Monitor electrolytes, renal function, fluid balance. Risk of hepatorenal syndrome if over-diuresed.

PBS status ✔ PBS General Benefit

💊

Midodrine

Gutron® · Alpha-1 agonist (vasopressor)

Adult dose 5–10 mg PO TDS (with meals), titrate to effect

Paediatric dose Not established

Renal adjustment Use with caution; no specific dose adjustment

Key notes Improves effective arterial blood volume in refractory ascites. May reduce need for large-volume paracentesis. Monitor supine hypertension.

PBS status ⚠ PBS Authority Required

Large-Volume Paracentesis (LVP)

For tense or refractory ascites, LVP (>5 L) provides rapid symptom relief. Albumin replacement (6–8 g per litre of ascites removed) is essential to prevent post-paracentesis circulatory dysfunction (PPCD), which increases the risk of renal impairment, hyponatraemia, and death. In palliative settings, serial LVP can be performed as an outpatient procedure every 2–4 weeks to control symptoms, balancing procedural burden against quality of life.

⚠️

Weight loss target with diuretics: Without peripheral oedema: aim for ≤0.5 kg/day weight loss. With peripheral oedema: ≤1 kg/day is acceptable. Exceeding these targets risks hepatorenal syndrome. If diuretics cannot maintain this, consider transition to paracentesis-based management.

Palliative Considerations

When ascites becomes truly refractory (diuretic-resistant despite maximum doses, or diuretic-intractable due to complications such as encephalopathy, renal impairment, or hyponatraemia), the focus shifts to symptom palliation via serial paracentesis. Patients should be counselled that refractory ascites is associated with a median survival of approximately 6 months. Early referral to palliative care enables symptom burden assessment, advance care planning, and family support. Insertion of an indwelling peritoneal catheter (e.g., PleurX®) may be considered in select palliative patients to avoid repeated paracentesis procedures, though evidence in ascites is limited and infection risk must be weighed against convenience.

Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome occurring in 30–45% of patients with cirrhosis. It profoundly affects quality of life, carer burden, and prognosis. Recurrent or persistent HE is an independent predictor of mortality and a key trigger for palliative care integration.

Classification

West Haven Grade	Features	Clinical Significance
Grade 0 (Covert)	Minimal HE — detected only by psychometric testing (e.g., Psychometric Hepatic Encephalopathy Score, PHES)	Impairs driving, employment; increased falls risk
Grade 1 (Mild)	Euphoria/depression, shortened attention span, impaired ability to add/subtract, altered sleep rhythm	Often underrecognised; affects medication adherence
Grade 2 (Moderate)	Lethargy, disorientation to time, asterixis, inappropriate behaviour	Usually warrants hospital admission; driving cessation
Grade 3 (Severe)	Somnolence but rousable, marked confusion, disorientation to place	Inpatient management; assess for precipitants
Grade 4 (Coma)	Unresponsive to verbal or painful stimuli	ICU consideration; goals-of-care discussion essential

Precipitants — Identify and Treat

HE is almost always precipitated by a reversible factor. Common precipitants in the Australian setting include:

Infection (SBP, UTI, pneumonia, cellulitis) — most common
GI bleeding (variceal or non-variceal)
Constipation
Electrolyte disturbance (hypokalaemia, hyponatraemia, metabolic alkalosis)
Dehydration or over-diuresis
Renal impairment / hepatorenal syndrome
Medications — benzodiazepines, opioids, antipsychotics, antihistamines
Dietary protein restriction (now discouraged; adequate protein intake is essential)
Transjugular intrahepatic portosystemic shunt (TIPS)

Pharmacological Management

💊

Lactulose

Duphalac® · Laevolac® · Osmotic laxative / ammonia reducer

Adult dose — acute HE 20–30 g (30–45 mL) PO/NG every 1–2 hours until bowel action, then titrate to 2–3 soft stools/day

Adult dose — maintenance 15–30 mL PO BD–TDS, titrated to 2–3 soft stools/day

Paediatric dose 0.5–1 mL/kg PO BD, titrated to effect

Renal adjustment No adjustment required; monitor for dehydration

Key notes First-line for both acute and prophylaxis of HE. Retention enema (300 mL in 700 mL water) if oral route unavailable. Caution: over-titration may cause dehydration and worsen encephalopathy.

PBS status ✔ PBS General Benefit

💊

Rifaximin

Xifaxan® · Non-absorbable antibiotic

Adult dose 550 mg PO BD, ongoing

Paediatric dose Not established for HE (used in travellers' diarrhoea from 12 years)

Renal adjustment No adjustment required (minimal systemic absorption)

Key notes Reduces risk of recurrent HE by ~50% when combined with lactulose. Also reduces hospitalisation for HE. Requires PBS Authority approval for HE prophylaxis.

PBS status ⚠ PBS Authority Required

💊

L-ornithine L-aspartate (LOLA)

Hepa-Merz® · Amino acid preparation

Adult dose IV: 20–40 g/day in 500 mL 5% dextrose or saline over 4 hours. Oral: 6 g TDS.

Renal adjustment Avoid in severe renal impairment (risk of hyperkalaemia/hyperuraemia)

Key notes May be used as adjunctive therapy in acute HE. Evidence base less robust than lactulose/rifaximin.

PBS status ✘ Not PBS-listed

Palliative Considerations in HE

⚠️

Prognostic significance: A third or subsequent episode of overt HE, or HE that becomes refractory to lactulose and rifaximin, is associated with a 12-month mortality exceeding 60%. This should trigger a formal palliative care assessment and goals-of-care discussion, including the option of comfort-focused care if consistent with patient wishes.

For patients in whom HE becomes persistent or recurrent despite maximal medical therapy, the focus of care should shift to symptom comfort and carer support. Aggressive bowel purgation in the dying patient with HE should be re-evaluated — comfort measures including mouth care, repositioning, and anxiolysis may be more appropriate. Families require education that HE-related behavioural changes (agitation, aggression, confusion) are part of the disease process and not reflective of the patient's character.

Bleeding Risk

Patients with ESLD have a paradoxical coagulopathy — they are simultaneously at risk of both haemorrhage (due to reduced synthesis of procoagulant factors and thrombocytopenia) and thrombosis (due to reduced anticoagulant factors such as protein C and S). Portal hypertension further compounds bleeding risk through the development of oesophageal and gastric varices.

Portal Hypertensive Bleeding

Variceal haemorrhage occurs in approximately 30% of patients with cirrhosis and medium-to-large varices. The first bleed carries a mortality of 15–20%. Re-bleeding rates are approximately 60% within 1–2 years without secondary prophylaxis. Each episode of variceal bleeding further decompensates the liver, increasing MELD score and mortality risk.

🚨

Emergency management of acute variceal bleeding:

Airway protection — consider early intubation if massive haematemesis or Grade 3–4 HE
Resuscitation with packed red blood cells (target Hb 70–80 g/L; avoid over-transfusion)
Vasoactive drug — IV terlipressin 2 mg q4h, or octreotide 50 µg IV bolus then 50 µg/hr infusion (continue for 3–5 days)
Prophylactic antibiotics — IV ceftriaxone 1 g daily for 5–7 days (reduces re-bleeding and mortality)
Urgent upper GI endoscopy within 12 hours for band ligation of oesophageal varices
Proton pump inhibitor — IV pantoprazole 40 mg BD if ulcers post-ligation
Avoid tranexamic acid in liver disease (limited benefit, potential thrombotic risk)

Coagulopathy in Advanced Liver Disease

Standard coagulation tests (INR, APTT) are poor predictors of bleeding risk in cirrhosis. An elevated INR reflects reduced procoagulant factors but does not account for the concomitant reduction in anticoagulant factors (protein C, S, antithrombin). Viscoelastic testing (rotational thromboelastometry — ROTEM®) provides a more accurate assessment of global haemostasis in cirrhosis and is increasingly available in Australian tertiary centres.

Haemostatic Abnormality	Mechanism	Management
Thrombocytopenia	Hypersplenism, reduced thrombopoietin	Platelet transfusion if <50 × 10⁹/L pre-procedure; thrombopoietin agonist (avatrombopag) if elective procedure
Elevated INR	Reduced procoagulant factor synthesis	Do not routinely correct with FFP — INR is unreliable; use ROTEM if available
Fibrinolysis	Reduced clearance of tissue plasminogen activator	Cryoprecipitate if fibrinogen <1.0 g/L; tranexamic acid only in selected cases
DIC	Portal hypertensive gastropathy, infection, HRS	Treat underlying cause; haematology consultation

Pharmacological Agents for Bleeding

💊

Terlipressin

Glypressin® · Vasopressin analogue

Adult dose 2 mg IV bolus, then 1–2 mg IV every 4–6 hours for 3–5 days

Renal adjustment Use with caution; may exacerbate hyponatraemia

Key notes Reduces portal pressure and controls bleeding in ~80% of cases. Risk of ischaemic events (peripheral, mesenteric, cardiac). Contraindicated in septic shock. Monitor for hyponatraemia.

PBS status ✘ Not PBS-listed (hospital authority)

💊

Octreotide

Sandostatin® · Somatostatin analogue

Adult dose 50 µg IV bolus, then 50 µg/hr continuous infusion for 3–5 days

Renal adjustment No adjustment required

Key notes Alternative to terlipressin. Fewer ischaemic side effects. Reduce dose for secondary prophylaxis as subcutaneous injection. Monitor blood glucose (may cause hyperglycaemia or hypoglycaemia).

PBS status ⚠ PBS Restricted Benefit

Palliative Considerations in Bleeding

For patients with recurrent variceal bleeding who are not transplant candidates, the goals of care must be discussed openly. Repeated endoscopic interventions, ICU admissions, and transfusions may not align with the patient's wishes, particularly when quality of life is poor. Non-selective beta-blockers (propranolol, carvedilol) and repeat banding reduce re-bleeding risk but should be weighed against the patient's overall trajectory. In the last days of life, active bleeding may be managed symptomatically with sedation and comfort measures if consistent with the patient's advance care plan.

Transplant & Goals of Care

Liver transplantation (LT) offers the only curative option for decompensated cirrhosis. In Australia, approximately 1,000–1,200 liver transplants are performed annually across eight transplant centres (five adult, three paediatric). However, organ scarcity, strict eligibility criteria, and the progressive nature of ESLD mean that many patients will not receive a transplant. Palliative care must be integrated alongside transplant assessment — not deferred until transplant is declined.

Transplant Assessment — When to Refer

Referral to a transplant centre should be considered when:

MELD score ≥15 or Child-Pugh score ≥7 (class B or C)
First episode of decompensation (ascites, variceal bleeding, HE, jaundice)
Hepatocellular carcinoma within Milan criteria (single lesion ≤5 cm or up to 3 lesions each ≤3 cm)
Acute-on-chronic liver failure with organ failure

Early referral allows time for assessment, lifestyle modification, alcohol abstinence (minimum 6 months is typically required for ALD), and addressing absolute and relative contraindications.

Absolute and Relative Contraindications

Absolute Contraindications	Relative Contraindications
Active extrahepatic malignancy (excluding non-melanoma skin cancer)	Age >70 (individual assessment)
Active substance use disorder (alcohol, illicit drugs) without demonstrated abstinence	BMI >35 kg/m²
Severe, irreversible cardiopulmonary disease	Non-adherence to medical therapy
Active uncontrolled sepsis	Portal vein thrombosis (complete, extensive)
Hepatocellular carcinoma beyond Milan criteria	Psychiatric illness without adequate social support

Goals of Care Conversations

Goals-of-care (GOC) conversations in ESLD are complicated by prognostic uncertainty, the potential for transplant, and the fluctuating nature of decompensation (patients may recover from an acute episode, creating a "hope–despair" cycle). Key principles include:

Initiate early: At the time of first decompensation or MELD ≥15, not when death is imminent.
Be honest about uncertainty: "We cannot predict exactly how long you have, but your liver is struggling and we need to plan for all possibilities."
Use the "surprise question": "Would I be surprised if this patient died in the next 12 months?" If the answer is "no," palliative care referral is appropriate.
Discuss realistic options: Transplant candidacy, active disease management, and comfort-focused care are not mutually exclusive — patients can be on a transplant waiting list while receiving palliative care for symptom management.
Address the full spectrum: Preferred place of care, resuscitation status (including ICU admission), intubation/ventilation, dialysis (if hepatorenal syndrome develops), and what "quality of life" means to the patient.
Involve family/whānau: Carer burden in ESLD is high, particularly with recurrent HE and dependence for activities of daily living.

✅

Concurrent palliative and transplant care: Australian and international guidelines (Palliative Care Australia, AASLD, EASL) now recommend that palliative care be introduced alongside, not instead of, curative or transplant-directed therapy. Patients who receive concurrent palliative care report better symptom control, reduced anxiety, and no reduction in survival.

Decompensation Scoring and Prognostication

Score	Components	Palliative Relevance
MELD / MELD-Na	Bilirubin, INR, creatinine (+ sodium)	MELD ≥20: 3-month mortality >20%. MELD ≥30: ~50% 3-month mortality.
Child-Pugh	Bilirubin, albumin, INR, ascites, HE	Class C: 1-year survival ~45%.
CLIF-C OF / CLIF-SOFA	Organ failure score in acute-on-chronic liver failure	≥3 organ failures: ICU mortality >70%.
Royal Free Hospital Palliative Care Score	MELD-Na, HE grade, serum sodium, white cell count, age	Specifically designed for palliative care needs assessment in cirrhosis.

End-of-Life Symptom Management in ESLD

The final days and weeks of life in ESLD are characterised by multi-organ failure, refractory ascites, worsening encephalopathy, and profound fatigue. Symptom management must account for impaired hepatic drug metabolism.

💊

Morphine

MS Contin® · Kapanol® · Opioid analgesic

Adult dose in ESLD Start at 50% of standard dose (e.g., 2.5 mg SC q4h PRN); titrate slowly. Avoid sustained-release formulations initially.

Key notes Active metabolites (M6G) accumulate in hepatic and renal impairment. Reduce dose and extend interval. Monitor for respiratory depression. Short-acting formulations preferred.

PBS status ✔ PBS General Benefit

💊

Midazolam

Hypnovel® · Benzodiazepine (sedation)

Adult dose — terminal sedation 2.5–5 mg SC/IV q1h PRN, or continuous infusion 0.5–1 mg/hr, titrated to comfort

Key notes Useful for terminal restlessness and dyspnoea. In ESLD, half-life is prolonged; use lower doses and titrate carefully. May be combined with morphine for refractory dyspnoea.

PBS status ⚠ PBS Restricted Benefit

💊

Haloperidol

Serenace® · Butyrophenone antipsychotic

Adult dose — agitation/nausea 0.5–2.5 mg SC/PO/IV q6–8h PRN

Key notes First-line for terminal delirium/agitation (superior to benzodiazepines in non-HE delirium). Also effective for nausea. Avoid in Parkinson's disease. Monitor QTc interval. Risk of extrapyramidal side effects at higher doses.

PBS status ✔ PBS General Benefit

💊

Hyoscine butylbromide

Buscopan® · Anticholinergic (secretion reducer)

Adult dose 20 mg SC q4–6h PRN for death rattle

Key notes Reduces upper airway secretions in the dying patient. Subcutaneous route preferred. Glycopyrrolate 200 µg SC is an alternative. Effectiveness limited but provides comfort for family.

PBS status ✔ PBS General Benefit

Special Populations

🤰

Pregnancy

Spironolactone

Category B3 — antiandrogenic effects in animal studies. Generally avoided in pregnancy; frusemide is preferred if diuretic therapy required.

Rifaximin

Category B1 — limited human data. Use only if benefit clearly outweighs risk. Lactulose is preferred as first-line for HE in pregnancy.

Terlipressin

Not studied in pregnancy. Potential uterotonic effects. Use only in life-threatening variceal bleeding with maternal–fetal medicine input.

Opioids (morphine)

Use lowest effective dose for shortest duration. Risk of neonatal respiratory depression and withdrawal. Short-acting agents preferred.

General considerations

Cirrhosis in pregnancy is rare but carries high maternal and fetal morbidity. All patients with liver disease of childbearing age should receive contraception counselling. Pregnancy is an absolute contraindication to transplantation.

👶

Paediatrics

Common causes

Biliary atresia (most common indication for paediatric liver transplant), Alagille syndrome, alpha-1 antitrypsin deficiency, Wilson disease, autoimmune hepatitis.

Lactulose

0.5–1 mL/kg PO BD, titrated to 2–3 soft stools/day. Safe in children.

Spironolactone

1–3 mg/kg/day PO in 1–2 divided doses. Monitor potassium and renal function.

Palliative care

Paediatric palliative care for liver disease requires a multidisciplinary team including child life therapists, social workers, and spiritual care. Family-centred care with attention to siblings and parental mental health is essential. In Australia, each state has a dedicated paediatric palliative care service.

👴

Elderly (≥65 years)

Frailty assessment

Frailty is highly prevalent in elderly patients with cirrhosis (>50%) and independently predicts waitlist mortality and poor post-transplant outcomes. The Liver Frailty Index (grip strength, chair stands, balance) should be assessed at each review.

Polypharmacy

Review medications regularly. Hepatic drug metabolism is further impaired with age. Avoid nephrotoxic and hepatotoxic agents where possible. Benzodiazepines carry high risk of falls and over-sedation.

Transplant candidacy

Age >70 is a relative contraindication in Australia. Physiological age (frailty) is more important than chronological age. Some centres will consider carefully selected patients aged 65–70.

End-of-life care

Elderly patients with ESLD may prefer symptom management over aggressive intervention. Goals-of-care conversations should explore values, preferred place of death, and the balance between longevity and quality of life.

🫘

Renal Impairment

Hepatorenal syndrome (HRS)

HRS-AKI (type 1): rapidly progressive (doubling of creatinine to >226 µmol/L within 2 weeks). Median survival without treatment: 2 weeks. HRS-CKD (type 2): slowly progressive, associated with refractory ascites. Median survival: 6 months.

Treatment of HRS-AKI

Terlipressin 1 mg IV q4–6h + IV albumin 1 g/kg (max 100 g) on day 1, then 20–40 g/day. If no response in 3 days, increase terlipressin to 2 mg q4h. Discontinue if no improvement at day 14 or if adverse effects. Noradrenaline infusion (0.5–3 µg/min) is an alternative in ICU settings.

Drug adjustments

Spironolactone: avoid if eGFR <30 mL/min. Frusemide: higher doses may be needed but risk dehydration. Rifaximin: no adjustment (minimal systemic absorption). Opioids: significant dose reduction required (accumulation of active metabolites).

Palliative focus

Renal replacement therapy (RRT) is generally not recommended in ESLD with multi-organ failure unless the patient is a transplant candidate with an anticipated short wait time. HRS-AKI that does not respond to terlipressin + albumin has near-universal mortality; this should prompt a goals-of-care conversation.

🟡

Hepatic Impairment (Severe / End-Stage)

All medications

In Child-Pugh C cirrhosis (score 10–15), hepatic clearance of virtually all medications is reduced. Phase I metabolism (CYP450) is more impaired than phase II (glucuronidation). Morphine (phase II) is relatively preserved compared with codeine (phase I), but active metabolites still accumulate.

Dosing principle

"Start low, go slow" — use 50% of standard doses for hepatically cleared drugs, titrate to effect, and monitor closely. Prefer renally cleared agents where possible (e.g., gabapentin over pregabalin for neuropathic pain, though both require dose adjustment).

Paracetamol

Safe at ≤2 g/day in chronic liver disease (reduced from standard 4 g/day). Avoid in acute liver failure. First-line analgesic for mild–moderate pain.

Avoid

NSAIDs (risk of GI bleeding, renal impairment, fluid retention), codeine (erratic metabolism, constipation worsens HE), tramadol (serotonin syndrome risk with concurrent medications, seizure threshold lowered).

🛡️

Immunocompromised Patients

Infection risk

Patients with ESLD have impaired innate and adaptive immunity (reduced complement, reticuloendothelial dysfunction, neutrophil dysfunction). Infection is the most common precipitant of acute-on-chronic liver failure and carries high mortality (>30% per episode).

Common infections

SBP, UTI, pneumonia, skin/soft tissue infections (including cellulitis from oedema), spontaneous bacteraemia, and Clostridioides difficile infection. Multidrug-resistant organisms (ESBL-producing Enterobacterales, MRSA, VRE) are increasingly common in Australian hospitals.

Vaccination

Pneumococcal (Prevenar 13 + Pneumovax 23), influenza (annually), hepatitis A and B (if non-immune), COVID-19 (including boosters). Vaccine response may be reduced in advanced liver disease.

Antimicrobial selection

Empirical antibiotics should cover Gram-negative organisms. For SBP: ceftriaxone 2 g IV daily. In hospital-acquired infections or recent antibiotic use: consider piperacillin–tazobactam or meropenem based on local antibiograms. Always consult local infectious disease guidelines.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Australians experience chronic liver disease at 3–5 times the rate of non-Indigenous Australians and are significantly more likely to die from liver disease, particularly in remote and very remote areas. Liver disease is the seventh leading cause of death for Aboriginal and Torres Strait Islander people, compared with the twentieth for non-Indigenous Australians. The age of onset is younger, progression is faster, and access to specialist hepatology and palliative care is significantly more limited.

🚨

Health inequity: Aboriginal and Torres Strait Islander patients with ESLD are less likely to be referred for transplant assessment, less likely to receive palliative care, and more likely to die in hospital rather than in their preferred place of care. Systemic and institutional racism, distrust of the healthcare system, and inadequate cultural safety in mainstream services contribute to these disparities.

Aetiology

Hepatitis B is disproportionately prevalent in Aboriginal and Torres Strait Islander communities (particularly in the Northern Territory, with rates 3–5 times the national average). ALD rates are significantly higher, driven by complex sociohistorical determinants. NASH is rising with increasing rates of obesity and type 2 diabetes.

Remote and rural access

Specialist hepatology and palliative care services are concentrated in metropolitan centres. In the Northern Territory, Western Australia, and Far North Queensland, patients may need to travel >1,000 km for specialist review. Telehealth (MBS item 99) and visiting specialist services partially address this, but gaps remain.

Cultural safety

Palliative care must be delivered in a culturally safe manner, acknowledging the role of family, Country, community, and cultural/spiritual practices. The concept of "end of life" may not align with Western biomedical frameworks. Aboriginal and Torres Strait Islander health workers and liaison officers must be involved in goals-of-care conversations. Sorry Business (mourning practices) may affect treatment decisions and care planning.

Advance care planning

Advance care planning rates are very low among Aboriginal and Torres Strait Islander Australians. Conversations should be initiated by clinicians with established rapport, ideally with an Aboriginal health worker present. Documents should be stored in My Health Record and communicated to relevant services including Aboriginal Community Controlled Health Organisations (ACCHOs).

Preferred place of death

Many Aboriginal and Torres Strait Islander patients express a strong preference to return to Country for end-of-life care. This requires coordination between hospital, community palliative care, ACCHOs, and remote health services. Medication supply (particularly parenteral opioids) in remote communities is a significant logistical challenge that must be planned for proactively.

Palliative care referrals

Under-referral of Aboriginal and Torres Strait Islander patients to palliative care is well documented. The Australian Institute of Health and Welfare (AIHW) reports that Aboriginal and Torres Strait Islander people access specialist palliative care at less than half the rate of non-Indigenous Australians. Clinicians must proactively offer palliative care and frame it as "extra support" rather than "giving up."

ℹ️

Key resource: The RHDAustralia (Remote Health Domestic Australia) and Palliative Care Australia "Roadmap for Aboriginal and Torres Strait Islander Palliative Care" provides practical guidance for culturally safe palliative care delivery in remote communities. All clinicians managing liver disease in Aboriginal and Torres Strait Islander patients should be familiar with this resource.

📚 References

1. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.
2. Biggins SW, Bambha KM. Palliative care in hepatology: a growing field. Hepatology. 2020;72(6):2202–2212.
3. Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis. Palliat Med. 2019;33(1):24–36.
4. Gastroenterological Society of Australia (GESA). Australian consensus guidelines for the management of chronic hepatitis B and hepatitis C infection 2023. J Gastroenterol Hepatol. 2023;38(Suppl 1):1–78.
5. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Liver disease. Canberra: AIHW; 2023.
6. Palliative Care Australia. National Palliative Care Standards. 5th ed. Canberra: Palliative Care Australia; 2018.
7. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735.
8. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974.
9. Rakoski MO, Volk ML. Palliative care for patients with end-stage liver disease: an overview. Clin Liver Dis (Hoboken). 2015;6(5):104–107.
10. Low JT, Rohde G, Pittordou K, et al. Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals. J Hepatol. 2018;69(6):1260–1273.
11. Transplantation Society of Australia and New Zealand (TSANZ). Organ transplantation from deceased donors: eligibility criteria and allocation protocols. Melbourne: TSANZ; 2023.
12. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol. 2017;15(10):1612–1619.e4.
13. Remote Health Domestic Australia (RHDAustralia). Top End Hepatitis B Clinical Resource Manual. Darwin: RHDAustralia, Northern Territory Department of Health; 2022.
14. Bajaj JS, Tandon P, O'Leary JG, et al. The impact of ICU admission and nutritional support on hepatic encephalopathy and mortality in cirrhosis. Am J Gastroenterol. 2022;117(7):1123–1132.
15. National Health and Medical Research Council (NHMRC). Statement on consumer and community involvement in health and medical research. Canberra: NHMRC; 2016.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).